On Wednesday, Shares of VF Corp (NYSE:VFC), subtract -0.92% and closed at $56.13 in the last trading session. The last trading range of the stock ranges between $55.91 and $56.57. V.F. Corporation engages in the design, production, procurement, marketing, and distribution of branded lifestyle apparel, footwear, and related products in the United States and Europe. The company mainly offers outdoor apparel, footwear and equipment, youth culture/action sports-inspired footwear, handbags, luggage, backpacks, totes, accessories, surfing-inspired footwear, merino wool socks, womens activewear, and travel accessories under the The North Face, Vans, Timberland, Kipling, Napapijri, Jansport, Reef, Smartwool, Eastpak, lucy, and Eagle Creek brands. It also provides denim, casual apparel, footwear, and accessories under the Wrangler, Lee, Lee Casuals, Riders by Lee, Rustler, Timber Creek by Wrangler, and Rock & Republic brands. In addition, the company offers occupational, protective occupational, athletic, licensed athletic, and licensed apparel products under the Red Kap, Bulwark, Horace Small, Majestic, MLB, NFL, and Harley-Davidson brands; sportswear apparel, luggage, and accessories under the Nautica brand; and handbags, luggage, backpacks, totes, and accessories under the Kipling brand. Further, it provides premium denim apparel, footwear, and accessories under the 7 For All Mankind, Splendid, and Ella Moss brands.
Cempra Inc (NASDAQ:CEMP), dropped -3.76% and closed at $6.40 in the last trading session. The last trading range of the stock ranges between $6.20 and $6.65. The company’s Market capitalization is $342.98 million with the total Outstanding Shares of 52.38 Billion. Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases in North America. Its lead product candidates include solithromycin (CEM-101), which is in Phase III clinical trials for the treatment of community attained bacterial pneumonia, in addition to for uncomplicated bacterial urethritis; and Taksta, an antibiotic that has accomplished Phase II clinical trials for refractory bone and joint infections. The company also produces novel macrolides for non-antibiotic uses, such as the treatment of chronic inflammatory diseases, endocrine diseases, and gastric motility disorders. It has collaborative research and development and license agreement with Optimer Pharmaceuticals, Inc.